HALIX Appoints Richard van Rijnsoever as Vice President of Business Development and Project Management
Leiden (The Netherlands, 07.02.2023) – HALIX, a leading cGMP contract development and manufacturing organization (CDMO) specialized on viral vectors, vaccines and therapeutic proteins, today announced the appointment of Richard van Rijnsoever to lead the company’s business development, marketing, and project management strategy and functions. Richard will report directly to Alex Huybens, CEO of HALIX, and will be based out of the Company’s headquarters in Leiden, the Netherlands.
“We are excited to have Richard onboard as we embark on our next chapter of growth at HALIX. His extensive experience in the biopharmaceutical industry, specifically the CDMO space, makes him uniquely qualified for this role,” said Alex Huybens, CEO of HALIX. “Richard’s expertise and knowledge will be invaluable in driving commercial growth, ensuring project management excellence, and helping us reach our ambitious goals.”
With more than 25 years of experience in the biopharmaceutical CDMO space, Richard brings a unique blend of commercial and project management expertise. Most recently, he served at NRG|PALLAS, a global market leader in producing nuclear isotopes for diagnosis, therapy and nuclear research, where he worked on the business case for the new-to-build PALLAS reactor and was responsible for the establishment of a new department concerning the commercialization of several therapeutic isotopes.
Prior to that, he held the role of Director of Business Development and Project Management at SynCo Bio Partners (later acquired by Wacker Biotech), a leading CDMO with expertise in manufacturing live microbial biopharmaceuticals and in filling finished pharmaceuticals. There, Richard was responsible for business development, sales, and marketing, as well as the strategic development of the company, and was member of the Management Team.
He holds a degree in Medical Biology from the Vrije Universiteit Amsterdam and began his career at IntroGene, one of the pioneering companies developing and manufacturing viral-based products for gene therapy vectors and vaccines, later merged with U-Bisys to form Crucell (now Janssen Vaccines), where he worked for 9 years in various roles within R&D and later in Business Development.
“I am delighted to join the HALIX team and to have the opportunity to drive commercial growth and a build a strong market presence,” said Richard. “HALIX has an impressive track record in the industry, and I am looking forward to contribute to their mission.”
About HALIX
HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca’s COVID-19 vaccine. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group AG.
More information is available on: www.halix.nl